| Crystalle M Evans, DO | |
|
1921 Stonecipher Dr, Ada, OK 74820-3439 | |
| (580) 421-4526 | |
| Not Available |
| Full Name | Crystalle M Evans |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 1921 Stonecipher Dr, Ada, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043560030 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 5209 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chickasaw Nation Medical Center | Ada, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chickasaw Nation Division Of Health | 8426957523 | 209 |
News Archive
Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.
Drew Armstrong, a health reporter for CQ HealthBeat, discusses House efforts to delay action on a Medicare "trigger" bill, health information technology legislation, an FDA tobacco regulation bill and steps toward passing mental health parity legislation in this week's "Health on the Hill from kaisernetwork.org and CQ."
Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients' quality of life and overall health. An emerging treatment option, however, could provide effective therapy for patients with these conditions.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.
A large study focused on documenting the strength and fitness of childhood brain tumor survivors has found that many face health challenges as they age. The study led by St. Jude Children's Research Hospital investigators showed that although most participants were young adults in their 20s, many functioned like people in their 60s, making them less likely to live independently or attend college.
› Verified 2 days ago
| Entity Name | Chickasaw Nation Division Of Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255364923 PECOS PAC ID: 8426957523 Enrollment ID: O20040108000364 |
News Archive
Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.
Drew Armstrong, a health reporter for CQ HealthBeat, discusses House efforts to delay action on a Medicare "trigger" bill, health information technology legislation, an FDA tobacco regulation bill and steps toward passing mental health parity legislation in this week's "Health on the Hill from kaisernetwork.org and CQ."
Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients' quality of life and overall health. An emerging treatment option, however, could provide effective therapy for patients with these conditions.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.
A large study focused on documenting the strength and fitness of childhood brain tumor survivors has found that many face health challenges as they age. The study led by St. Jude Children's Research Hospital investigators showed that although most participants were young adults in their 20s, many functioned like people in their 60s, making them less likely to live independently or attend college.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Crystalle M Evans, DO 1921 Stonecipher Dr, Ada, OK 74820-3439 Ph: () - | Crystalle M Evans, DO 1921 Stonecipher Dr, Ada, OK 74820-3439 Ph: (580) 421-4526 |
News Archive
Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.
Drew Armstrong, a health reporter for CQ HealthBeat, discusses House efforts to delay action on a Medicare "trigger" bill, health information technology legislation, an FDA tobacco regulation bill and steps toward passing mental health parity legislation in this week's "Health on the Hill from kaisernetwork.org and CQ."
Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients' quality of life and overall health. An emerging treatment option, however, could provide effective therapy for patients with these conditions.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.
A large study focused on documenting the strength and fitness of childhood brain tumor survivors has found that many face health challenges as they age. The study led by St. Jude Children's Research Hospital investigators showed that although most participants were young adults in their 20s, many functioned like people in their 60s, making them less likely to live independently or attend college.
› Verified 2 days ago
Dr. Christopher Goodwill, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Dr, Ada, OK 74820 Phone: 580-436-3980 Fax: 580-421-6283 | |
Melissa Kathleen Colbert, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Dr, Ada, OK 74820 Phone: 580-421-3980 | |
Mr. Joshua Medved, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Blvd, Ada, OK 74820 Phone: 580-421-4570 | |
Preston Hucks, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1921 Stonecipher Blvd, Ada, OK 74820 Phone: 580-421-4570 | |
Connie Marie Wilson, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Stonecipher Blvd, Ada, OK 74820 Phone: 580-421-4570 | |
Kent Denson, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 905 Colony Dr, Ada, OK 74820 Phone: 580-436-5111 Fax: 580-272-5731 |